Evaluation of the relationship between pentraxin 3 (PTX3) rs2305619 (281A/G) and rs1840680 (1449A/G) polymorphisms and the clinical course of COVID-19.
Adolescent
Adult
Alleles
C-Reactive Protein
/ genetics
COVID-19
/ genetics
Disease Progression
Female
Genotype
Humans
Macrophage Activation Syndrome
/ etiology
Male
Middle Aged
Polymorphism, Single Nucleotide
/ genetics
Risk Factors
Serum Amyloid P-Component
/ genetics
Severity of Illness Index
Young Adult
COVID-19
macrophage activation syndrome
pentraxin 3
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
05
07
2021
accepted:
24
07
2021
pubmed:
28
7
2021
medline:
28
10
2021
entrez:
27
7
2021
Statut:
ppublish
Résumé
Macrophage activation syndrome (MAS) is one of the main causes of morbidity and mortality in patients with coronavirus disease 2019 (COVID-19). This study aimed to investigate the relationship between the pentraxin 3 (PTX3) gene polymorphisms rs2305619 (281A/G) and rs1840680 (1449A/G) and the development of MAS in patients with COVID-19. The study included a total of 94 patients aged 18-45 who were diagnosed as having COVID-19 between June and December 2020. PTX3 281A/G and 1449A/G polymorphism frequencies were evaluated. PTX3 281A/G allele and genotype frequencies did not deviate from Hardy-Weinberg (HW) equilibrium in the MAS or non-MAS group (χ
Identifiants
pubmed: 34314051
doi: 10.1002/jmv.27238
pmc: PMC8426891
doi:
Substances chimiques
Serum Amyloid P-Component
0
PTX3 protein
148591-49-5
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6653-6659Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Clin Infect Dis. 2018 Jan 6;66(2):261-267
pubmed: 29020397
JCI Insight. 2020 Aug 6;5(15):
pubmed: 32554923
Front Immunol. 2018 Dec 19;9:3046
pubmed: 30619374
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
J Immunol. 2020 Sep 15;205(6):1488-1495
pubmed: 32699160
J Immunol. 2008 Mar 1;180(5):3391-8
pubmed: 18292565
Thromb Res. 2020 Aug;192:3-8
pubmed: 32407937
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
J Clin Nurs. 2020 Jul;29(13-14):2044-2046
pubmed: 32239784
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Front Immunol. 2019 Aug 02;10:1750
pubmed: 31428091
BMJ. 2020 Mar 13;368:m1052
pubmed: 32169830
Front Immunol. 2019 Apr 12;10:794
pubmed: 31031772
Clin Chim Acta. 2020 Oct;509:249-251
pubmed: 32579952
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Lung. 2020 Oct;198(5):777-784
pubmed: 32918573
J Med Virol. 2021 Dec;93(12):6653-6659
pubmed: 34314051
PLoS One. 2012;7(12):e53030
pubmed: 23285251
Egypt J Immunol. 2017 Jan;24(1):21-27
pubmed: 29120574
Chest. 2018 Feb;153(2):361-367
pubmed: 29248620
Ann N Y Acad Sci. 2013 May;1285:1-14
pubmed: 23527487